

RESEARCH ARTICLE

The global cost of epilepsy: A systematic review and extrapolation

Charles Begley¹  | Ryan G. Wagner²  | Annette Abraham^{3,4} | Ettore Beghi⁵  | Charles Newton⁶ | Churl-Su Kwon⁷  | David Labiner⁸ | Andrea S. Winkler^{3,4} 

¹School of Public Health, University of Texas Health Science Center, Houston, Texas, USA

²MRC/Wits Rural Public Health and Health Transitions Research Unit, School of Public Health, University of the Witwatersrand, Parktown, South Africa

³Department of Neurology, Center for Global Health, Technical University of Munich, Munich, Germany

⁴Centre for Global Health, Institute of Health and Society, University of Oslo, Oslo, Norway

⁵Mario Negri Institute for Pharmacological Research, Milan, Italy

⁶Department of Psychiatry, Oxford University, Oxford, UK

⁷Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York, USA

⁸Department of Neurology, University of Arizona College of Medicine, Tucson, Arizona, USA

Correspondence

Charles Begley, School of Public Health, University of Texas, 875 Serene Woods Circle, Canyon Lake, Houston, TX 78133, USA.
Email: Charlesebegley@gmail.com

Abstract

Objective: Global action for epilepsy requires information on the cost of epilepsy, which is currently unknown for most countries and regions of the world. To address this knowledge gap, the International League Against Epilepsy Commission on Epidemiology formed the Global Cost of Epilepsy Task Force.

Methods: We completed a systematic search of the epilepsy cost-of-illness literature and identified studies that provided a comprehensive set of direct health care and/or indirect costs, followed standard methods of case identification and cost estimation, and used data on a representative population or subpopulation of people with epilepsy. Country-specific costs per person with epilepsy were extracted and adjusted to generate an average cost per person in 2019 US dollars. For countries with no cost data, estimates were imputed based on average costs per person of similar income countries with data. Per person costs for each country were then applied to data on the prevalence of epilepsy from the Global Burden of Disease collaboration adjusted for the treatment gap.

Results: One hundred one cost-of-illness studies were included in the direct health care cost database, 74 from North America or Western Europe. Thirteen studies were used in the indirect cost database, eight from North America or Western Europe. The average annual cost per person with epilepsy in 2019 ranged from \$204 in low-income countries to \$11 432 in high-income countries based on this highly skewed database. The total cost of epilepsy, applying per person costs to the estimated 52.51 million people in the world with epilepsy and adjusting for the treatment gap, was \$119.27 billion.

Significance: Based on a summary and extrapolations of this limited database, the global cost of epilepsy is substantial and highly concentrated in countries with well-developed health care systems, higher wages and income, limited treatment gaps, and a relatively small percentage of the epilepsy population.

KEYWORDS

cost, epilepsy, global, per person, prevalence, regional, total

Charles Begley is retired.

© 2022 International League Against Epilepsy

1 | INTRODUCTION

The 73rd Session of the World Health Assembly's resolution calling for the development of a global action plan for epilepsy requires global, regional, and country-specific knowledge of the cost of epilepsy.¹ Cost-of-illness (COI) studies may be used to help policymakers set priorities by showing the economic value in reducing the burden of a specific disease and providing important information for cost-effectiveness and cost-benefit analyses of prevention and treatment strategies. Prior efforts to compile this information for epilepsy have been limited to systematic reviews of individual country studies (most recently Allers et al. and Strzelczyk et al.),^{2,3} extrapolation of cost estimates from multiple studies for the United States,⁴ and extrapolation of cost estimates for all countries in Western Europe based on studies from some of the countries.^{5,6} To address this gap in information, the International League Against Epilepsy (ILAE) Commission on Epidemiology formed the Global Cost of Epilepsy Task Force (TF) to estimate the total cost of epilepsy worldwide, including direct health care costs (payments by individuals, governments, insurers, and fiduciary organizations for epilepsy-specific treatment) and indirect costs (lost earnings of people with epilepsy and their caregivers related to absence from work, excess unemployment, reduced productivity at work, and excess mortality).

The project had to address numerous challenges to develop the global cost estimates. Existing COI studies in epilepsy are still largely limited to direct health care cost studies from high-income countries with very few from middle-income, and less than a handful from low-income countries. Existing studies are difficult to compare due to the substantial variation in methods used, such as differences in study perspective (incidence vs. prevalence, societal vs. government), cost items included, identification procedures used, sources of data, population sampled, and time frame.⁷ In addition, differences in the relative prices and availability of treatments must be addressed. Finally, whereas the epidemiologic literature focuses on determining the number of people with active epilepsy in a population, the COI literature includes people with inactive epilepsy (previously diagnosed but in remission) and active epilepsy who receive treatment and incur costs.

2 | MATERIALS AND METHODS

Employing an approach similar to that used for global studies in dementia⁸ and regionally for epilepsy,^{5,6} we conducted a systematic search of epilepsy COI studies throughout the world, extracted costs presented in these studies, and made several adjustments to generate a single estimate of per person and total epilepsy-attributable

Key Points

- Based on review and extrapolations of cost data from the existing epilepsy cost-of-illness literature, this study estimates the direct and indirect cost of epilepsy worldwide and shows the distribution by region and income
- The average cost per person with epilepsy was estimated to be \$4467 per year in 2019, ranging from \$204 in low-income countries to \$11 432 in high-income countries
- Applying average costs to the estimated prevalence of 52.5 million cases, and adjusting for the treatment gap, total epilepsy costs were \$119.27 billion
- Most of the costs are in the wealthiest countries, where a minority of the world's epilepsy population reside

direct health care and indirect cost for people with epilepsy by country in 2019 US dollars (USD). We then estimated per person and total costs for countries with no data based on the median cost per person in countries in the same income category with data adjusted to reflect health care expenditures and income in each country. We then applied the estimates to the latest available data on epilepsy prevalence in each country from the Global Burden of Disease (GBD) collaboration, adjusted health care costs for the treatment gap, and aggregated to arrive at regional and global costs.⁹

2.1 | Literature search

To search the COI literature, prespecified criteria were applied to electronic databases, including MEDLINE (via PubMed), Embase, EBSCOhost, Web of Science, and Scopus. Search strategies were developed for each database, combining one or more disease-related search term with one or more cost-related search term. The specific search protocol, following PRISMA guidelines,¹⁰ is available as Appendix S1. The protocol was registered with PROSPERO (CRD42020178600).

Articles identified from each search were uploaded to the Covidence systematic review online software (Covidence Systematic Review Software; Veritas Health Innovation, www.covidence.org), where duplicates were automatically excluded, and a four-stage review process was conducted. In Stage 1, two TF members independently reviewed the titles, abstracts, and/or summaries, to exclude studies based on the following criteria:

1. Studies published prior to January 1, 2000.
2. Purely modeling studies.
3. Letters to the editor or commentaries.
4. Lack of per person cost estimates.
5. Lack of definitions of epilepsy used to identify cases.
6. Focus on an incomplete set of therapies, interventions, or cost items.
7. Not population-based (i.e., data from single site or provider).

Studies were limited to those published after 2000 due to the introduction of newer antiseizure medications around this time, which likely result in lower cost estimates (and hence, outdated costs) in earlier studies.

In Stage 2, articles not excluded in Stage 1 were then reviewed independently in their entirety by two members of the TF to ensure studies met the following inclusion criteria:

1. Empirical estimates of total or per person direct health care and/or indirect costs for people with epilepsy.
2. Estimates based on the general epilepsy population or a representative sample of subpopulations (e.g., adult or pediatric patients, controlled or drug-resistant epilepsy, with or without comorbidity, on different types of medication) that can be generalized.
3. Discernible case identification criteria and procedures.

4. Clear description of the design, data sources, and procedures for identifying epilepsy-attributable costs.

Selected articles then underwent a quality assessment in Stage 3. The process involved two members of the TF independently assessing each article based on four criteria: (1) accuracy of case identification, (2) representativeness of cases, (3) accuracy of cost identification and attribution, and (4) comprehensiveness of costs. Each reviewer scored the article on each criterion as 1 = low, 2 = moderate, and 3 = high, based on specific definitions used for each that are available in Figure 1. Only articles with moderate or high-quality scores across all four criteria were selected.

In Stage 4, selected articles were randomly assigned to one member of the TF, who extracted the per person cost estimates from the article using a predesigned RedCAP questionnaire.¹¹ The extracted data were then independently confirmed by a second member of the TF. The resultant database was exported from RedCAP as an Excel Spreadsheet (Microsoft) and used in the analysis.

2.2 | Calculation of country-specific per person cost estimates

The focus of the cost data extracted from selected studies varied in terms of perspective, coverage time frame,

1. Accuracy of epilepsy diagnoses

[Requires (a) clear evidence of recurrent epileptic seizures, with evidence that these are unprovoked by any acute medical condition or transient brain disorder or (b) documentation of diagnosis by someone with appropriate specialized training in the recognition of epilepsy.]

- 3 - High, primary documentation that meets criterion (a) or (b) above
- 2 - Moderate, administrative, or self-report data indicating the likelihood that criterion (a) or (b) is met
- 1 - Low, where primary or other sources of information suggest a possibility of epilepsy but neither criterion (a) nor (b) is met

2. Completeness of epilepsy case-finding

- 3 - High, methods likely to ascertain 70% or more of cases
- 2 - Moderate, methods likely to ascertain 50% or more of cases
- 1 - Low, methods unlikely to ascertain majority of cases or unable to assess

3. Accuracy of costs

- 3 - High, comparative method to identify costs that represent the difference between total costs for people with epilepsy (or specific epilepsy condition) and a comparable group of people without epilepsy (or other epilepsy condition)
- 2 - Moderate, bottom-up based on acceptable method to identify cost of epilepsy-related services
- 1 - Low, reported total direct or indirect costs only

4. Completeness of costs

- 3 - High, direct costs include inpatient hospitalizations, outpatient visits and procedures, and medications over an identified time period. Indirect costs include illness-related unemployment, work absence, and productivity earnings losses
- 2 - Moderate, direct costs include hospitalizations and another major cost item. Indirect costs include lost earnings from illness-related absence from work and either excess unemployment or reduced productivity at work
- 1 - Low, limited to one direct or indirect cost item

FIGURE 1 Quality assessment scoring criteria. The figure describes the criteria and scoring for assessing the quality of the cost studies that were reviewed

population, types of epilepsy, severity, types of therapy, and age group. A number of adjustments were made to these data to develop estimates of the average direct health care cost per person for the general population of people with epilepsy in a given country.

2.2.1 | Costs for brand versus generic drug users

The weighted average of cost estimates was derived with weights based on the distribution of cases on each type of drug.

2.2.2 | Costs for drug-resistant versus stable patients

The weighted average of the cost estimates was used based on the distribution of cases by type, if available from the study, or 20/80 weights for drug-resistant/stable, based on the distribution of cases typically found in the cost literature.^{12–15}

2.2.3 | Costs for individuals in different parts of a country or treatment settings

The weighted average was used based on the distribution of cases by setting from the study, if available, or a simple average was used.

2.2.4 | Costs reported for different age groups

Weighted average was used based on distribution of cases by age group when available. If not, the simple average cost for all ages was used.

2.2.5 | Costs for multiple years

The midpoint year or simple average of all years was used.

2.2.6 | Costs for year of onset and follow-up years

The weighted average of the cost estimates was used based on the distribution of cases, if available, or 15/85 incidence/prevalence weights from the cost literature.^{12,13}

2.2.7 | Costs for patients on different numbers of antiseizure medications or different antiseizure medication brands

The weighted average was used based on the distribution of cases in the study.

2.2.8 | Costs for patients with different severity of epilepsy (i.e., based on seizure frequency, emergency room visit or hospitalization, number of changes in drug use, etc.)

The weighted average was used based on the distribution of cases in the study.

2.2.9 | Costs for patients with drug-resistant epilepsy only

The costs could not be used for the general epilepsy population.

2.2.10 | Costs for patients with “active/inactive” epilepsy

The selected studies defined inactive cases as in remission for 1 or more years. Weights were used based on distribution of cases by type, if available, or 15/85 inactive/active weights based on the distribution of cases found in the cost literature.^{12,13}

A number of studies of direct health care costs also included estimates of indirect costs, and a few studies were found that estimated indirect costs only. The indirect cost estimates from these studies included lost earnings associated with epilepsy-related absence from work, excess unemployment, reduced productivity at work, and premature mortality for people with epilepsy and their caregivers. Some used wages and others gross domestic product (GDP) per capita to value lost earnings, and the groups for which indirect costs were presented (patients only, patients and caregivers, employed patients only, employable age patients only, etc.) varied. Like direct health care costs, we adjusted the data from the 13 selected studies of indirect costs to generate a comparable indirect cost per person estimate for all people with epilepsy at the country level. All the studies had to include costs based on absence from work plus either excess unemployment or reduced productivity or both. A few studies also included earnings losses associated with premature mortality. When the

study reported total indirect costs for selected subgroups (workers, working age, adults, etc.) in a given country, we divided the costs by the total epilepsy population (including those with no indirect costs) to derive indirect cost per person.

Both the direct health care and indirect cost data were for various years and reported in various currencies. To adjust the costs to 2019 USD, we followed standard methods¹⁶ using the World Bank GDP inflation deflator¹⁷ for the relevant country to adjust for inflation from the study year to 2019 and the World Bank 2019 Purchasing Power Parity exchange rate¹⁸ to convert to USD.

When cost data for a given country were available from multiple studies, the unweighted mean of all available estimates was used for the country. The median was considered but not used due to the relatively small number of countries with three or more studies. In some cases where one study estimate was an outlier from the others, and there was a discernible methodological rationale for the difference, it was excluded.

2.3 | Extrapolations for countries with no cost data

The direct health care cost database included estimates from multiple countries within each World Bank income category (low income, lower-middle income, upper-middle income, and high income). Either the average or the median (depending on the number and range) among countries with data in each category was used to estimate costs for similar income countries with no data. To reflect the variation among countries within income category, the cost for a given country was adjusted by an index of the relative health expenditure per capita¹⁹ within the country compared to other countries in the same income category. Health spending per capita was selected for the adjustment index because it had the strongest correlation with epilepsy costs across the countries with data (Pearson correlation coefficient of .75) compared to GDP per capita (.64) and the GBD Socio-demographic Index (a compound measure of income per capita, education, and fertility; .47).

The median indirect cost per person of countries in similar income categories was adjusted by an index of the relative GDP per capita²⁰ of the country compared to the income group average to estimate indirect cost per person for countries without data. GDP per capita was selected for the indirect cost adjustment because it had the strongest correlation with indirect cost of epilepsy across countries with data (Pearson correlation coefficient of .74) compared to health spending per capita (.57), and the GBD Socio-demographic Index (.52).

2.4 | Developing global costs

The inflation- and currency-adjusted epilepsy-specific per person costs were then multiplied by the latest estimates of the number of people with epilepsy in 195 individual countries available from the GBD study and aggregated at GBD super region, World Bank income category grouping,²¹ and global levels. The GBD collaboration is the most comprehensive initiative to measure levels and geographic and temporal trends of diseases and injuries worldwide (<http://www.healthdata.org/gbd/about/protocol>). The collaboration provides estimates of prevalence, incidence, premature mortality, and disability for more than 300 diseases and injuries in 195 countries, by sex and age from 1990 to the present, with comparisons over time, within populations and countries. The 2019 estimates of epilepsy prevalence, which are the latest available, refer to idiopathic epilepsy and other epilepsies caused by infectious agents (i.e., meningitis, tetanus, malaria, cysticercosis, cystic echinococcosis), preterm birth complications, neonatal encephalopathy, neonatal sepsis, neonatal hemolytic disease, brain cancer, traumatic brain injury, congenital anomalies, and stroke. GBD estimates include people having seizures (active epilepsy) and those in remission (inactive epilepsy). Although these figures may underestimate the entire burden of idiopathic and symptomatic epilepsy as defined by the ILAE,²² they represent the most comprehensive estimate of the number of people with epilepsy in whom epilepsy-specific direct health care and indirect costs can be attributed.

2.5 | Sensitivity analysis

The health care cost per person data from the COI literature overestimate the actual health care cost of epilepsy per person in countries due to the epilepsy treatment gap (e.g., people who are not diagnosed or receiving treatment for their epilepsy).²³ To adjust our estimates accordingly, data from the most comprehensive treatment gap literature survey available to date²⁴ were applied to each country's epilepsy prevalence based on its income category (65% for low-income, 52% for lower-middle-income, 55% for upper-middle-income, and 10% high-income countries) before multiplying by per person health care costs to calculate total health care costs.

In the global COI literature, GDP per capita has also been shown to be correlated with disease-specific cost data and used to adjust regional cost estimates in imputing costs for countries without data.⁷ To determine the sensitivity of the results to using GDP per capita to adjust median values of cost rather than health care spending,

we generated estimates with both and compared the difference.

3 | RESULTS

3.1 | Literature search

Using the search criteria and procedures outlined above, 17 067 references were identified in the initial electronic search (Figure 2), of which 9649 were duplicates, 7075 were excluded based on review of titles and abstracts, and of these, 54 review articles were identified. One hundred fifty-five of the remaining 343 were excluded after full text review; 80 only provided total or partial cost estimates for people with epilepsy, 20 were found to be from the same study, and 55 did not present original empirical data or new analysis. One hundred eighty-eight articles remained and underwent a quality assessment. One hundred one studies met the quality requirements for the direct health care cost database: 46 in North America, 32 in Western Europe, four in Eastern Europe, one in Latin America, eight in East Asia, five in Central Asia, and five in Africa. Thirteen indirect cost studies were selected: four in Western Europe, four in East Asia, three in North America, one in Africa, and one in Eastern Europe.

3.2 | Cost estimates

Table 1 shows the 2019 cost per person estimates from the 101 selected studies for 22 countries with direct health care cost data and from the 13 studies for eight countries with indirect cost data by income category. Direct health care costs range from less than \$1 per person per year in Burundi to \$10 659 in Canada. The mean for low-income countries was \$55. The mean for high-income countries

was \$4476. Indirect costs ranged from \$150 in Nigeria to \$14 206 in Denmark.

Based on the per person costs for countries with cost data and extrapolations for the remaining countries (173 without direct health care cost data and 187 without indirect cost data), the worldwide average annual cost of epilepsy per person in 2019 is estimated at \$4467 (the sum of direct health care cost per person [\$1687] and indirect cost per person [\$2780]; Table 2, Row 5, Columns 4 and 8, respectively). Direct health care spending ranged from \$54 in low-income to \$3160 in high-income countries and indirect costs ranged from \$150 in low-income to \$8272 in high-income countries. The total cost of epilepsy, assuming average direct health care and indirect costs apply to all 52.51 million people in the world with epilepsy (GBD estimate for 2019), is \$145.91 billion: 54% direct and 46% indirect. Adjusting direct health care costs for existing estimates of the treatment gap, total epilepsy costs fall to \$119.27 billion: 44% direct and 56% indirect. Using GDP per capita rather than health care spending per capita to extrapolate direct health care costs for countries with no data increased per person average direct health care costs slightly to \$1775 and lowered total costs to \$143.75 billion (not included in the table). Individual country estimates are available as Appendix S2.

The distribution of costs does not reflect the distribution of cases. As shown in the table, most of the costs are in 62 high-income countries (71% of total costs not considering the treatment gap, 83% including the treatment gap), with only 15% of the world's epilepsy population. Only about 6% of the costs of epilepsy are in the 78 low- and lower-middle-income countries, where 50% of the population with epilepsy resides. The cost figure in these countries accounts for only 4% of global costs when the treatment gap is considered.

The concentration of costs is also reflected at the regional level (Table 3), with 64% of total costs (75%




FIGURE 2 PRISMA diagram of systematic review of cost-of-illness studies. The figure describes the resulting number of cost studies after each stage of the literature search

TABLE 1 Direct health care and indirect cost data extracted from the cost-of-illness literature

Country	Direct health care cost per person, 2019 USD	Indirect cost per person, 2019 USD	World Bank income category ^a
Burundi	\$.57		1
Congo	\$108.44		1
Mean	\$54.50		1
India	\$53.82		2
Nigeria	\$654.59	\$149.56	2
Mean	\$354.20		2
Bulgaria	\$3062.26		3
Mexico	\$1666.00		3
China	\$449.23	\$321.23	3
Russia	\$2470.20		3
Mean	\$2048.20		3
Australia	\$2525.00		4
Hungary	\$553.81		4
Poland	\$657.23	\$1520.80	4
Korea	\$1166.39	\$2123.31	4
Netherlands	\$2191.77		4
UK	\$2320.76		4
Sweden	\$2403.25	\$13 632.37	4
Denmark	\$4157.36	\$14 205.64	4
Italy	\$4498.33		4
Spain	\$6988.86	\$11 058.91	4
Germany	\$7095.51		4
France	\$7464.71		4
USA	\$9984.04	\$5924.50	4
Canada	\$10 659.16		4
Mean	\$4476.16	\$6117.04	4

^a1, low income; 2, lower-middle income; 3, upper-middle income; 4, high income.

considering the treatment gap) found in 31 countries located in Australia/New Zealand, South Asia, North America, and Western Europe, where only 12% of the population with epilepsy lives.

4 | DISCUSSION

The global cost of epilepsy is substantial but varies significantly across countries depending on the prevalence of epilepsy, costs per person, and the epilepsy treatment gap. The latter two are highly correlated with income, resulting in the concentration of costs in high-income countries and regions of the world, whereas most of the population living with epilepsy resides in low- and middle-income countries and regions. The cost of epilepsy includes substantial indirect as well as direct health care costs, given its chronic nature and effects over the life course. The latter varies with the development of the health care system

and access to health care. The former is associated with employment opportunity and wage levels in each country.

Epilepsy direct health care costs are relatively low compared to other more common disease conditions, based on the limited comparisons available. For example, our estimate of the 2019 direct health care cost of epilepsy worldwide (\$78.95 billion) was 50% of the 2015 estimate of the health care cost of dementia.²⁵ Health care costs for epilepsy in the United Kingdom in 2019 were \$955.86 million in our study compared to dementia (\$1.57 billion), cancer (\$3.96 billion), coronary heart disease (\$2.16 billion), and stroke (\$1.65 billion).²⁵ Estimates of the indirect cost of these conditions are not available for comparison, but given that epilepsy affects young as well as older subjects, the work-related indirect health care costs over a person's lifetime may be relatively more important.

These findings provide support for policy and program advocacy that target direct health care as well as indirect

TABLE 2 Prevalence (GBD 2019) and cost (2019 US dollars) by World Bank income category

Country	Prevalence, 2019 (GBD)	%	Health care cost per person	Total health care cost, thousands	%	Total health care cost considering treatment gap, thousands	Indirect cost per person	%	Total indirect cost, thousands	%	Total health care and indirect cost, thousands	%	Total health care and indirect cost considering treatment gap, thousands	%
Low income, <i>n</i> = 29	4 527 579	8.6	\$54	\$219 693	.3	\$29 419	\$150	.1	\$647 622	1.0	\$867 314	.6	\$677 040	.6
Lower-middle income, <i>n</i> = 49	21 665 389	41.3	\$359	\$4 305 968	5.5	\$1 278 872	\$150	2.4	\$2 843 243	4.3	\$7 149 210	4.9	\$4 122 115	3.5
Upper-middle income, <i>n</i> = 55	18 262 503	34.8	\$1986	\$28 540 300	36.1	\$9 618 081	\$319	18.4	\$6 184 054	9.2	\$34 724 854	23.8	\$15 802 135	13.2
High income, <i>n</i> = 62	8 056 182	15.3	\$3160	\$45 883 792	58.1	\$41 387 180	\$8272	79.1	\$57 279 162	85.5	\$103 162 954	70.7	\$98 666 342	82.7
Total countries, <i>n</i> = 195	52 511 653	100.0	\$1687	\$78 954 207	100.0	\$52 314 137	\$2780	100.0	\$66 954 079	100.0	\$145 908 287	100.0	\$119 268 216	100.0

Abbreviation: GBD, Global Burden of Disease.

costs of epilepsy and reflect the conditions in different regions of the world. In high-income countries, the high cost of health care and high indirect costs suggest a focus on improving efficiency in health care delivery, ensuring equity in access, and reducing costs of care while also addressing barriers to employment and work productivity of people living with epilepsy. In lower income regions of the world, the relatively low cost of the disease reflects the lack of available health care services and employment opportunities. Additional investments are needed to expand access to services for the general population and educate the population on the benefits of treatment.

As the first study to generate country, regional, and global estimates of the cost of epilepsy, the TF was able to follow a general approach that has been used in cross-country cost studies for epilepsy. Where choices had to be made, we chose methods that were as objective and transparent as possible. The results are conservative but reasonable when compared to previous research from 13 review articles published since 2000.^{26–46} Thirty-nine direct health care cost per person estimates for 12 countries were adjusted to 2019 USDs and compared with ours. Differences ranged from 86% below to 49% above, with an overall average difference of 10% below. The average direct health care cost per person quoted in the review articles for all studies was \$2839 per year compared to our average of \$2454 for the same studies we compared.

Our estimates for Western European countries are comparable to those from the European Brain Study (EBS),⁶ the only other multicountry regional cost study to date. Substantial differences in prevalence and cost were found overall between the EBS study and our estimates after updating the EBS cost estimates to 2019 USD (Table 4). The TF prevalence figures are 21% higher than the EBS prevalence estimates, only a part of which can be explained by population growth (1.5% in 2010–2019). The direct health care and indirect cost per person are 53% lower and 27% higher, respectively, compared to the EBS. The TF total cost estimate for the region is 8% lower than the EBS estimate when not including the treatment gap and 12% lower when including the treatment gap.

Most cost estimates from the COI literature are based on subpopulations of people with the disease that must be adjusted to the general population. The best method for aggregating to the general population would be to multiply the cost for people in different subpopulations by the prevalence estimates of each subpopulation.⁷ This approach is impractical for multicountry cost studies, given the lack of detailed epidemiological and cost data. The TF developed a systematic approach for generating general population estimates from subpopulation data without detailed data that involved (1) deriving weighted averages of subpopulation estimates for treatment groups based on

TABLE 3 Prevalence (GBD 2019) and cost (2019 US dollars) by GBD superregion

GBD superregion	Prevalence, 2019 (GBD)	Direct health care cost per person	Total direct health care cost, thousands	Total direct health care cost considering treatment gap, thousands	%	Indirect cost per person	Total indirect cost, thousands	Total direct health care and indirect cost, thousands	Total direct health care and indirect cost considering treatment gap, thousands	%
Central Europe, Eastern Europe, and Central Asia; 29 countries	2 968 537	5.7	\$4 141 508	\$1 797 853	5.2	\$1583	\$3 184 214	\$7 325 722	\$4 982 067	4.2
Australasia, South Asia, North America (high income); 8 countries	3 491 634	6.6	\$28 034 204	\$25 286 852	35.5	\$8879	\$22 450 054	\$50 484 258	\$47 736 906	40.0
Southern Latin America; 3 countries	418 764	.8	\$1 868 413	\$791 336	2.4	\$2488	\$707 886	\$2 576 299	\$1 499 222	1.3
Western Europe; 23 countries	2 828 374	5.4	\$15 491 532	\$13 973 362	19.6	\$11 505	\$27 424 819	\$42 916 351	\$41 398 181	34.7
Latin America and Caribbean; 32 countries	5 909 182	11.3	\$14 570 657	\$5 024 127	18.5	\$2060	\$2 860 007	\$17 430 664	\$7 884 134	6.6
North Africa and Middle East; 21 countries	3 928 880	7.5	\$4 521 966	\$1 829 492	5.7	\$2343	\$3 728 808	\$8 250 774	\$5 558 300	4.7
South Asia; 5 countries	12 993 217	24.7	\$909 810	\$270 213	1.2	\$104	\$1 386 313	\$2 296 124	\$1 656 528	1.4
Sub-Saharan Africa; 46 countries	5 157 409	9.8	\$1 983 659	\$635 737	2.5	\$153	\$720 023	\$2 703 681	\$1 355 759	1.1
Southeast Asia, East Asia, and Oceania; 28 countries	14 815 656	28.2	\$7 432 459	\$2 705 165	9.4	\$709	\$4 491 955	\$11 924 414	\$7 197 119	6.0
Total; 195 countries	52 511 653	100.0	\$78 954 207	\$52 314 137	100.0	\$2780	\$66 954 079	\$145 908 287	\$119 268 216	100.0

Abbreviation: GBD, Global Burden of Disease.

TABLE 4 Comparison: European Brain Study (2010 prevalence, cost literature extractions, extrapolations) versus ILAE TF Study (2019 prevalence, cost literature extractions, extrapolations)

2010 EU24, Iceland, Norway, Switzerland	Prevalence	Total cost per person, weighted average across countries	Total cost, billions	Total cost considering TG, billions	Direct health care cost per person, weighted average	Total direct health care cost, billions	Indirect costs per person, weighted average across countries	Total indirect costs, billions
European Brain Study	2 643 001	\$14 923	\$47.86	\$47.86	\$8531	\$22.55	\$7404	\$19.57
ILAE TF Study	3 185 238	\$13 479	\$43.94	\$42.32	\$4042	\$15.74	\$9437	\$28.20
Percent difference	20.52	−9.68	−8.18	−11.57	−\$53	−30.19	\$27	44.11

Abbreviations: ILAE, International League Against Epilepsy; TF, Global Cost of Epilepsy Task Force.

the distribution of people in different treatment categories available from either the study or COI literature, and (2) applying the estimated treatment gap percentage from the growing treatment gap literature to population prevalence to account for the lower direct cost of the untreated.

The major limitation of the TF estimates is the limited number and skewed nature of direct health care and indirect cost data at the country level, leading to the large number of extrapolations required in the analysis. The lack of indirect cost information from most countries in the world (not only concerning the patient but also the caregiver, especially in low- and middle-income countries) is even more pronounced, with only one study from a lower-middle-income country deemed to be of high enough quality to be included in the indirect cost database. Even when the information is available, it is difficult to aggregate and compare due to differing measures, sources, subpopulations, designs, and periods of time. For example, some cost studies reflect health care prices or tariffs set by the government or insurance companies that do not represent actual costs, thereby influencing the reported total cost. Acknowledging these limitations highlights the urgent need for undertaking high-quality COI studies particularly in low- and lower-middle-income countries around the world. More standardized studies of more representative samples of people with epilepsy from different parts of the world are needed to provide evidence on the distributional impact of epilepsy worldwide. It is the hope of this TF that these results can stimulate future research to better understand the nature and distribution of the economic burden of this often treatable, chronic condition.

ACKNOWLEDGMENTS

This report was written by experts selected by the ILAE and was approved for publication by the ILAE. Opinions expressed by the authors, however, do not necessarily represent the policy or position of the ILAE. All coauthors have been substantively involved in the study and/or the preparation of the manuscript. No undisclosed groups or persons have had a primary role in the study and/or in manuscript preparation. The authors wish to acknowledge Devind Peter and Puleng Khampepe at the University of the Witwatersrand's Faculty of Health Sciences Library for their assistance with the systemic review. All coauthors have seen and approved the submitted version of the paper and accept responsibility for its content.

CONFLICT OF INTEREST

None of the authors has any conflict of interest to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

ORCID

Charles Begley  <https://orcid.org/0000-0003-3205-7688>

Ryan G. Wagner  <https://orcid.org/0000-0003-2741-3676>

Ettore Beghi  <https://orcid.org/0000-0003-2542-0469>

Churl-Su Kwon  <https://orcid.org/0000-0001-9904-2240>

Andrea S. Winkler  <https://orcid.org/0000-0003-3131-6983>

REFERENCES

- Guekht A, Brodie M, Secco M, Li S, Volkers N, Wiebe S. The road to a World Health Organization global action plan on epilepsy and other neurological disorders. *Epilepsia*. 2021;62(5):1057–63.
- Allers K, Essue BM, Hackett ML, Muhunthan J, Anderson CS, Pickles K, et al. The economic impact of epilepsy: a systematic review. *BMC Neurol*. 2015;15:245.
- Strzelczyk A, Reese JP, Dodel R, Hamer HM. Cost of epilepsy: a systematic review. *Pharmacoeconomics*. 2008;26(6):463–76.
- Begley CE, Durgin TL. The direct healthcare cost of epilepsy in the United States: a systematic review of estimates. *Epilepsia*. 2015;56(9):1376–87.
- Andlin-Sobocki P, Jönsson B, Wittchen H-U, Olesen J. Costs of disorders of the brain in Europe. *Eur J Neurol*. 2005;12:1–27.
- Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jönsson B. The economic cost of brain disorders in Europe. *Eur J Neurol*. 2012;19(1):155–62.
- Gao L, Hu H, Zhao FL, Li SC. Can the direct medical cost of chronic disease be transferred across different countries? Using cost-of-illness studies on type 2 diabetes, epilepsy and schizophrenia as examples. *PLoS One*. 2016;11(1):1–17.
- Wimo A, Winblad B, Jönsson L. The worldwide societal costs of dementia: estimates for 2009. *Alzheimers Dement*. 2010;6(2):98–103.
- Institute for Health Metrics and Evaluation. Global health data exchange download 2019. <http://ghdx.healthdata.org/gbd-2019>. Accessed October 31, 2019.
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71. <https://doi.org/10.1136/bmj.n71>
- Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG, et al. Research Electronic Data Capture (REDCap)—a meta-data driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009;42(2):377–81.
- Giussani G, Canelli V, Bianchi E, Franchi C, Nobili A, Erba G, et al. A population-based study of active and drug-resistant epilepsies in Northern Italy. *Epilepsy Behav*. 2016;55:30–7.
- Beghi E, Garattini L, Ricci E, Cornago D, Parazzini F, EPICOS Group. Direct healthcare cost of medical management of epilepsy among adults in Italy: a prospective cost-of-illness study (EPICOS). *Epilepsia*. 2004;45(2):171–8.
- World Health Organization. Epilepsy: a public health imperative. 2019. <https://apps.who.int/iris/handle/10665/325440?show=full>. Accessed September 16, 2019.
- Kwan P, Brodie MJ. Early identification of drug-resistant epilepsy. *N Engl J Med*. 2000;342(5):314–9.
- Turner HC, Lauer JA, Tran BX, Teerawattananon Y, Jit M. Adjusting for inflation and currency changes within health economic studies. *Value Health*. 2019;22(9):1026–32.
- World Bank. Inflation, GDP deflator (annual %). 2020. <https://data.worldbank.org/indicator/NY.GDP.DEFL.KD.ZG>. Accessed July 15, 2021.
- World Bank 2019 PPP exchange rate. 2020. <https://data.worldbank.org/indicator/NY.GDP.DEFL.KD.ZG>. Accessed July 15, 2021.
- Global health expenditure database. Geneva, Switzerland: World Health Organization; 2017.
- World Bank. International Monetary Fund world economic outlook (October-2019). January 21, 2020. <https://statistics.times.com/economy/countries-by-gdp-capita.php#:~:text=World%20bank%20%20%20Rank%20%20,%20%202018%20%2071%20more%20rows%20>. Accessed July 15, 2021.
- World Bank. The world by income. <https://datatopics.worldbank.org/world-development-indicators/images/figures-png/world-by-income-sdg-atlas-2018.pdf>. Accessed July 15, 2021.
- Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. *Epilepsia*. 2017;58(4):522–30. <https://doi.org/10.1111/epi.13670>
- Meinardi H, Scott RA, Reis R, Sander JW, ILAE Commission on the Developing World. The treatment gap in epilepsy: the current situation and ways forward. *Epilepsia*. 2001;42(1):136–49.
- Kwon CS, Wagner RG, Carpio A, Jetté N, Newton CR, Thurman DJ. The worldwide epilepsy treatment gap: a systematic review and recommendations for revised definitions—a report from the ILAE Epidemiology Commission. *Epilepsia*. 2022. <https://doi.org/10.1111/epi.17112>.
- Wimo A, Guerchet M, Ali GC, Wu YT, Prina AM, Winblad B, et al. The worldwide costs of dementia 2015 and comparisons with 2010. *Alzheimer Dement*. 2017;13(1):1–7.
- Beghi E, Garattini L, Ricci E, Cornago D, Parazzini F, EPICOS Group. Direct cost of medical management of epilepsy among adults in Italy: a prospective cost-of-illness study (EPICOS). *Epilepsia*. 2004;45:171–8.
- Begley CE, Famulari M, Annegers JF, Lairson DR, Reynolds TF, Coan S, et al. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. *Epilepsia*. 2000;41(3):342–51.
- Berto P, Tinuper P, Viaggi S. Cost-of-illness of epilepsy in Italy—data from a multicentre observational study (Episcreen). *Pharmacoeconomics*. 2000;17(2):197–208. <https://doi.org/10.2165/00019053-200017020-00008>
- Bolin K, Lundgren A, Berggren F, Kallen K. Epilepsy in Sweden: health care costs and loss of productivity—a register-based approach. *Eur J Health Econ*. 2012;13(6):819–26. <https://doi.org/10.1007/s10198-011-0361-8>
- De Zelicourt M, Buteau L, Fagnani F, Jallon P. The contributing factors to medical cost of epilepsy: an estimation based on a French prospective cohort study of patients with newly diagnosed epileptic seizures (the CAROLE study). *Seizure*. 2000;9:88–95.
- Garcia-Contreras F, Constantino-Casas P, Castro-Rios A, Nevarez-Sida A, Estrada Correa Gdel C, Carlos Rivera F, et al. Direct medical costs for partial refractory epilepsy in Mexico.

- Arch Med Res. 2006;37(3):376–83. <https://doi.org/10.1016/j.arcmed.2005.07.005>
32. Guerrini R, Battini R, Ferrari AR, Veggiotti P, Besana D, Gobbi G, et al. The costs of childhood epilepsy in Italy: comparative findings from three health care settings. *Epilepsia*. 2001;42:641–6.
 33. Halpern M, Rentz A, Murray M. Cost of illness of epilepsy in the US: comparison of patient-based and population-based estimates. *Neuroepidemiology*. 2000;19(2):87–99.
 34. Hong Z, Qu B, Wu XT, Yang TH, Zhang Q, Zhou D. Economic burden of epilepsy in a developing country: a retrospective cost analysis in China. *Epilepsia*. 2009;50(10):2192–8.
 35. Jennum P, Gyllenberg J, Kjellberg J. The social and economic consequences of epilepsy: a controlled national study. *Epilepsia*. 2011;52(5):949–56. <https://doi.org/10.1111/j.1528-1167.2010.02946.x>
 36. Kotsopoulos IA, Evers SM, Ament AJ, Kessels FGH, de Krom MCTFM, Twellaar M, et al. The costs of epilepsy in three different populations of patients with epilepsy. *Epilepsy Res*. 2003;54(2–3):131–40.
 37. Libby AM, Ghushchyan V, McQueen RB, Slejko JF, Bainbridge JL, Campbell JD. Economic differences in direct and indirect costs between people with epilepsy and without epilepsy. *Med Care*. 2012;50:928–33.
 38. Noda AH, Hermsen A, Berkenfeld R, Dennig D, Endrass G, Kaltofen J, et al. Evaluation of costs of epilepsy using an electronic practice management software in Germany. *Seizure*. 2015;26:49–55.
 39. Nsengiyumva G, Druet-Cabanac M, Nzisabira L, Preux PM, Vergnenegre A. Economic evaluation of epilepsy in Kiremba (Burundi): a case-control study. *Epilepsia*. 2004;45(6):673–7.
 40. Sancho J, Pena P, Rufo M, Palacios G, Masramon X, Rejas J, et al. Health and non-health care resources use in the management of adult outpatients with drug-resistant epilepsy in Spain: a cost-of-illness study (LINCE study). *Epilepsy Res*. 2008;81(2–3):176–87. <https://doi.org/10.1016/j.eplepsyres.2008.05.008>
 41. Strzelczyk A, Schubert-Bast S, Reese JP, Rosenow F, Stephani U, Boor R. Evaluation of health-care utilization in patients with Dravet syndrome and on adjunctive treatment with stiripentol and clobazam. *Epilepsy Behav*. 2014;34:86–91.
 42. Strzelczyk A, Nickolay T, Bauer S, Haag A, Knake S, Oertel WH, et al. Evaluation of health-care utilization among adult patients with epilepsy in Germany. *Epilepsy Behav*. 2012;23:451–7.
 43. Tetto A, Manzoni P, Millul A, Beghi E, Garattini L, Tartara A, et al. The costs of epilepsy in Italy: a prospective cost-of-illness study in referral patients with disease of different severity. *Epilepsy Res*. 2002;48(3):207–16.
 44. Thomas SV, Sarma PS, Alexander M, Pandit L, Shekhar L, Trivedi C, et al. Economic burden of epilepsy in India. *Epilepsia*. 2001;42(8):1052–60. <https://doi.org/10.1046/j.1528-1157.2001.04200.81052.x>
 45. Wilner AN, Sharma BK, Soucy A, Krueger A. Health plan paid cost of epilepsy in 2009 in the US. *Epilepsy Behav*. 2012;25:412–6.
 46. Yoon D, Frick KD, Carr DA, Austin JK. Economic impact of epilepsy in the United States. *Epilepsia*. 2009;50(10):2186–91. <https://doi.org/10.1111/j.1528-1167.2009.02159.x>

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.

How to cite this article: Begley C, Wagner RG, Abraham A, Beghi E, Newton C, Kwon C-S, et al. The global cost of epilepsy: A systematic review and extrapolation. *Epilepsia*. 2022;63:892–903. <https://doi.org/10.1111/epi.17165>